TITLE

Medicare Needs More Data Before Covering Amyloid Scans

AUTHOR(S)
Sullivan, Michele G.
PUB. DATE
March 2013
SOURCE
Neurology Reviews;Mar2013, Vol. 21 Issue 3, p22
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on issues pertaining to reimbursement of doctors who performed a positron emission tomography (PET). As mentioned, the U.S. Centers for Medicare and Medicaid Services refused to reimburse stating that these tests do not fall under three categories for such scans. It also adds that the criteria include mild cognitive impairment, dementia or dementia at a young age.
ACCESSION #
86412310

 

Related Articles

  • [F]Flutemetamol amyloid-beta PET imaging compared with [C]PIB across the spectrum of Alzheimer's disease. Hatashita, Shizuo; Yamasaki, Hidetomo; Suzuki, Yutaka; Tanaka, Kumiko; Wakebe, Daichi; Hayakawa, Hideki // European Journal of Nuclear Medicine & Molecular Imaging;Feb2014, Vol. 41 Issue 2, p290 

    Purpose: The aim was to identify the amyloid beta (Aβ) deposition by positron emission tomography (PET) imaging with the F-labeled Pittsburgh compound B (PIB) derivative [F]flutemetamol (FMM) across a spectrum of Alzheimer's disease (AD) and to compare Aβ deposition between [F]FMM and...

  • Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease. Yakushev, Igor; J. Muller, Matthias; Buchholz, Hans-Georg; Lang, Ulrike; Rossmann, Heidi; Hampel, Harald; Schreckenberger, Mathias; Fellgiebel, Andreas // Current Alzheimer Research;Feb2012, Vol. 9 Issue 2, p241 

    Cerebral hypometabolism and abnormal levels of amyloid beta (Aβ), total (t-tau) and phosphorylated tau (ptau) proteins in cerebrospinal fluid (CSF) are established biomarkers of Alzheimer's disease (AD). We examined the agreement between these biomarkers in a single center study of patients...

  • Registry Participation Qualifies NaF-PET for CMS Reimbursement.  // Radiology Today;Mar2011, Vol. 12 Issue 3, p41 

    The article reports on the decision of the Centers for Medicare and Medicaid Services to reimburse sites participating in the National Oncologic PET Registry (NOPR) for F-18 sodium fluoride (NaF)-positron emission tomography (PET) scans. It states that Naf-NPET scans has a higher diagnostic...

  • CMS opens NCA for PET as diagnostic.  // Medical Device Daily;1/8/2009, Vol. 13 Issue 4, p2 

    The article focuses on the decision of the U.S. Centers for Medicare & Medicaid Services (CMS) to conduct a national coverage analysis for the use of positron-emission tomography (PET) as a first-line diagnosis for suspected cancer. The accumulation of data urged CMS to consider PET for routine...

  • MITA; CMS blew it on PET/Alzheimer's.  // Medical Device Daily;7/11/2013, Vol. 17 Issue 132, p9 

    The article reports on the announcement made by the Centers for Medicare & Medicaid Services that it will offer only conditional coverage of positron emission tomography (PET) imaging for detection of the beta amyloid characteristic of alzheimer's disease.

  • CMS’ PET peeve. GOOZNER, MERRILL // Modern Healthcare;9/21/2015, Vol. 45 Issue 38, p0024 

    The article focuses on the Positron Emission Tomography (PET) scans, which function by injecting radioactive tracers into the blood of patients, and identify the hot spots inside the patient body. It compares the working and efficiency of PET scans with Computerized Axial Tomography (CT) scan...

  • Medicare May Reimburse for Amyloid Imaging Only in Trials. Sullivan, Michele G. // Neurology Reviews;Aug2013, Vol. 21 Issue 8, p22 

    The article focuses on the development of patient medicare under the Coverage with Evidence Development (CED) program by the Centers for Medicare and Medicaid Services (CMS) that will reimburse for the amyloid brain imaging. It informs that beta-amyloid imaging with positron emission tomography...

  • PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost? Mitka, Mike // JAMA: Journal of the American Medical Association;3/20/2013, Vol. 309 Issue 11, p1099 

    The article informs that radiologists can now detect human brain β-amyloid plaques, one of the pathological features of Alzheimer disease using positron emission tomography (PET). It informs that the technology will help in earlier diagnosis and treatment for patients with Alzheimer disease...

  • CMS to cover NaF-18 PET for bone metastases under CED. McCARTY, MARK // Medical Device Daily;3/12/2010, Vol. 14 Issue 48, p1 

    The article reports on the decision of the U.S. Centers for Medicare & Medicaid Services (CMS) to apply the coverage with evidence (CED) development rubric to reimburse for the utilization of a radioisotope of sodium fluoride for metastatic bone cancer. According to the announcement of CMS on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics